| |
| Xpention
Genetics, Inc. is
a biotechnology company that was formed to develop both immunological
and molecular tests
for cancer detection in animals and humans as well as therapeutic
vaccines and other treatment methods for both veterinary and
human cancers. Xpention through its subsidiary has licensed,
exclusive rights to a specific genetic marker called the
p65 that has highly specific correlation
to numerous cancers. |
| |
|
 |
| |
|
|
| |
|
Vaccine
Work |
| |
|
|
|
|
Following
development of the molecular assay, the company will pursue development
of therapeutic vaccines utilizing RNAi (interference RNA) technology.
Any changes in the genetic dynamic of P65 will steer cells toward
abnormal growth resulting in tumor development. The hallmark
of P65 alteration is a pronounced increase in the level of gene
expression.
Other oncogenes such as ERB2 are found to be elevated primarily
in breast cancer. It has been shown that once the level of ERB2
goes back to normal, cancer growth slows down or disappears.
Xpention’s approach to vaccine development relies on the
use of RNAi technology. RNAi is a novel technique capable of manipulating
the level of a target gene by “interfering” with its
genetic expression. This technology has been successfully applied
to a variety of genetic targets including cancer and viral genes.
Xpention is developing adenoviral vector based delivery systems
that contain genetic elements unique to P65 sequences. By interfering
with the genetic machine responsible for the altered levels of
P65 in cancer cells, Xpention aims to revert or slow down the neoplastic
process. An “in vitro” and mouse model for P65 related
cancer growth has already been developed. The company will also
employ the “Integrated technology platform system” (ITPS)
to determine the efficacy of adenovirus vector RNAi based vaccine
(AVVRNAi). Levels of p65 are measured before and at different time
points after AVVRNAi injections in mice. Different dosages of vaccine
will be used to determine the proper concentrations based on the
highest levels of P65 gene inhibition. ITPS will greatly expedite
the preclinical stage of the P65 vaccine development allowing a
faster and more efficient start of human clinical studies. |
|
